Reference entry · ACTH fragment analog
Semax
Also known as: ACTH(4-10) analog · MEHFPGP · Met-Glu-His-Phe-Pro-Gly-Pro
- Class
- ACTH fragment analog
- Size
- 7 amino acids
- Primary targets (literature)
- BDNF signaling, neurotrophin pathways (literature); no single dominant receptor
- Regulatory context
- Registered as a drug in Russia for defined indications; not FDA-approved. Catalog Semax is RUO material distinct from any pharmaceutical formulation.
Overview
Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment developed in Russian neuropharmacology programs. Western-indexed literature explores neurotrophic gene expression, BDNF-related signaling, and neuroprotection in rodent models.
Mechanism in research literature
Published models propose modulation of neurotrophin expression, dopaminergic and serotonergic systems, and stress-response pathways — without a single well-characterized GPCR target comparable to melanocortin or ghrelin agonists.
Common research focus areas
- BDNF and neurotrophin expression in rodent models
- Stroke and hypoxia neuroprotection assays
- Gene-expression profiling after Semax exposure
- Parent sequence vs. N-acetyl/amidate derivatives
Full literature roundup
Read the cited research summary
An ACTH(4-10) analog with extensive neuropharmacology literature. Neurotrophin signaling, preclinical models, and catalog identity verification.
Semax research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.